Engineering immune response to regulate cardiovascular disease and cancer

• Published in: Advances in protein chemistry and structural biology Vol. 140; pp. 381 - 417
• Main Authors: Rani, Diksha, Kaur, Smaranjot, Shahjahan, Dey, Joy Kumar, Dey, Sanjay Kumar
• Format: Journal Article
• Language: English
• Published: Netherlands 2024
• Subjects: Adaptive Immunity - immunology; Animals; Cardiovascular Diseases - immunology; Gastrointestinal Microbiome - immunology; Humans; Immunity, Innate - immunology; Immunotherapy; Neoplasms - immunology; Neoplasms - therapy; CVD; Immune-engineering; Cancers; Immune-therapeutics; Immune system
• ISSN: 1876-1631
• DOI: 10.1016/bs.apcsb.2023.12.004

Cardiovascular disease (CVD) and cancer are major contributors to global morbidity and mortality. This book chapter delves into the intricate relationship between the immune system and the pathogenesis of both cardiovascular and cancer diseases, exploring the roles of innate and adaptive immunities, immune regulation, and immunotherapy in these complex conditions. The innate immune system acts as the first line of defense against tissue damage and infection, with a significant impact on the initiation and progression of CVD and cancer. Endothelial dysfunction, a hallmark in CVD, shares commonalities with the tumor microenvironment in cancer, emphasizing the parallel involvement of the immune system in both conditions. The adaptive immune system, particularly T cells, contributes to prolonged inflammation in both CVD and cancer. Regulatory T cells and the intricate balance between different T cell subtypes influence disease progression, wound healing, and the outcomes of ischemic injury and cancer immunosurveillance. Dysregulation of immune homeostasis can lead to chronic inflammation, contributing to the development and progression of both CVD and cancer. Thus, immunotherapy emerged as a promising avenue for preventing and managing these diseases, with strategies targeting immune cell modulation, cytokine manipulation, immune checkpoint blockade, and tolerance induction. The impact of gut microbiota on CVD and cancer too is explored in this chapter, highlighting the role of gut leakiness, microbial metabolites, and the potential for microbiome-based interventions in cardiovascular and cancer immunotherapies. In conclusion, immunomodulatory strategies and immunotherapy hold promise in reshaping the landscape of cardiovascular and cancer health. Additionally, harnessing the gut microbiota for immune modulation presents a novel approach to prevent and manage these complex diseases, emphasizing the importance of personalized and precision medicine in healthcare. Ongoing research and clinical trials are expected to further elucidate the complex immunological underpinnings of CVD and cancer thereby refining these innovative approaches.